This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy International Europe

Savings Deadline Expires In:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
2-4 December 2024
Convention Centre DublinDublin, Ireland

Eric Halioua
President & Chief Executive Officer at PDC*line Pharma
Speaker

Profile

Serial entrepreneur that combines strong strategic, technological and managerial experience with proven track record of deal-making and fund-raising. During his career he achieved together with his different teams to bring four drug candidates from research to the clinics (up to phase IIb). Overall, Eric has raised as of now a total of more than €170 million from VCs and strategic partners in Europe, USA, Japan and Korea and have had numerous successes in the sale and initial public offering of biotechnology companies.

He is CEO of the biotechnology company PDC*line Pharma and board member of Essenscia (Bio.be). Eric is co-founder of four biotechnology companies called Myosix (bought by Genzyme mid-2002), Murigenetics, HairClone and Digital Orthopaedics. He is co-Inventor of the first GMP approved mobile manufacturing unit for cell therapy.

Eric worked for 12 years in the Healthcare and Life Sciences Practice of Arthur D. Little. Eric holds two master’s degrees in pharmacology and Molecular Biology and a MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair.

Agenda Sessions

  • New class of Antigen-specific Cancer Active Immunotherapies based on an off-the-shelf Antigen Presenting Cell line (PDC*line)

    14:00
  • Fuelling Funding: Securing the Future Innovation and Development of Advanced Therapies & Biologics in Ireland & Beyond

    16:15